|1.||Watson, S A: 3 articles (03/2007 - 12/2000)|
|2.||Michaeli, D: 2 articles (12/2001 - 12/2000)|
|3.||Smith, A M: 2 articles (12/2001 - 12/2000)|
|4.||Justin, T: 2 articles (12/2001 - 12/2000)|
|5.||Gilliam, A D: 1 article (03/2007)|
|6.||Morris, T: 1 article (12/2001)|
|7.||Hartwich, A: 1 article (09/2000)|
|8.||Hahn, E G: 1 article (09/2000)|
|9.||Konturek, S J: 1 article (09/2000)|
|10.||Konturek, P C: 1 article (09/2000)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
12/01/2000 - "Fifty patients with advanced colorectal cancer were treated with G17-DT in a multicenter, sequential group, open label Phase I/II study. "
12/01/2000 - "G17-DT immunization produces anti-G17 antibodies in patients with advanced colorectal cancer. "
03/16/1998 - "Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin."
12/01/2000 - "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer."
03/16/1998 - "Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model."
02/15/1996 - "The tumor was implanted into the muscle layer of the abdominal wall, and rats immunized with Gastrimmune had significantly reduced median cross-sectional tumor areas (70.2% reduction; P = 0.005) and weights (56.5% reduction; P = 0.0078)) when compared to control rats. "
02/15/1996 - "Histological analysis revealed that the tumors had an enhanced degree of necrosis, with the area of viable tumor in the Gastrimmune-immunized rat reduced to 40.3% compared to 58.6% in the control rats (P = 0.003). "
03/16/1998 - "Gastrimmune (200 microg.ml(-1)) and 5-FU/leucovorin combinations (12.5 and 20 mg.kg(-1)) increased the therapeutic effects on the in vivo growth of DHDK12 tumors when compared to the agents given singly. "
02/15/1996 - "Immunization with Gastrimmune raised antibodies that inhibited the growth of a rat colon tumor. "
09/25/2000 - "Reduction of gastrin by active immunisation (gastrimmune), blocking of gastrin receptors with specific blockers and suppression of COX-2 might be helpful in inhibiting tumor growth and invasion."
|3.||Stomach Neoplasms (Stomach Cancer)
12/01/2000 - "Additional dose-ranging studies have been performed in patients with gastric cancer using 100- and 200-microg doses of G17-DT formulated without adjuvant and the emulsifier aluminum monostearate. "
12/01/1999 - "To investigate the therapeutic effect of antibodies, raised against the Gastrimmune immunogen, which neutralise the glycine extended and carboxy amidated forms of gastrin 17 in two human gastric cancer models. "
04/12/1999 - "The therapeutic effect of antibodies raised by the immunogen Gastrimmune was compared with both a CCKB/gastrin receptor antagonist, CI-988, and 5-Fluorouracil/leucovorin in a gastric cancer model. "
|4.||Neoplasm Metastasis (Metastasis)
08/01/1999 - "In addition Gastrimmune-induced antiserum limited the growth of lung metastasis as assessed by nodule number (controls = 3.5; antibody-treated = 1.0; P = 0.0001) and nodule cross-sectional as assessed by image analysis (controls = 11.9 mm2; antibody-treated = 3.75 mm2; P = 0.0064). "
08/01/1999 - "Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV."
|3.||Cholecystokinin B Receptor
|5.||stearic acid (magnesium stearate)
|6.||Glycine (Aminoacetic Acid)
|8.||Leucovorin (Folinic Acid)
|9.||gastrin 17 (G 17)